Business Wire

Philip Morris International Names New External Affairs Leader

Share

Philip Morris International Inc. (PMI) (NYSE: PM) is pleased to announce the appointment of Christos Harpantidis to the position of Senior Vice President, External Affairs effective May 1, 2024. In his new role, Mr. Harpantidis will report to the company’s CEO, Jacek Olczak.

“Christos is an experienced business leader with a proven track record of engaging society on the benefits of tobacco harm reduction and risk-proportionate regulation for smoke-free products,” said CEO Jacek Olczak. “He has been instrumental in building our smoke-free business in Greece and the South East Europe Area as we evolve away from cigarettes. I’m looking forward to working with Christos and excited to see what opportunities we can unlock as he takes the helm of our External Affairs function globally.”

Since joining PMI in 2003, Mr. Harpantidis has held several positions, including setting the commercialization strategy for smoke-free products in Lausanne, Switzerland, and serving as Chairman and Managing Director of Papastratos in Greece. Most recently, he served as Area Vice President of the South East Europe Area. Throughout his career at PMI, he has strongly contributed to growing the company’s smoke-free consumer base, expanding its brand portfolio, and advocating for regulations consistent with PMI’s smoke-free ambitions. Prior to joining the company, he worked at Coca-Cola Hellenic. Mr. Harpantidis holds a degree in physics from the Aristotle University of Thessaloniki, Greece, as well as master’s degrees in economics and business administration from Kent University in the United Kingdom.

“Leading our dynamic External Affairs function globally is an enormous honor,” said Christos Harpantidis. “I look forward to building on the remarkable progress already achieved by the team, which is resulting in science-based tobacco harm reduction policies being endorsed by more countries. I am incredibly proud of the work we are doing to transform our company and of the way civil society is coming together to support us. Still, more must be done. To realize our world-changing vision, we must continue to engage in transparent dialogue, build trust in the evidence, and work closely with policymakers and public health stakeholders to accelerate change.”

This appointment follows the decision of Grégoire Verdeaux to leave PMI at the end of April to pursue other professional opportunities. During his tenure, Mr. Verdeaux expanded the company’s global tobacco harm reduction strategy and, with the team, built compelling policy positions and advocated for regulations consistent with our smoke-free ambitions.

“Thanks, in large part, to Grégoire’s efforts, tobacco harm reduction policies are now endorsed by a growing number of countries,” said Mr. Olczak. “Under Christos’ leadership, I believe that the External Affairs function will ensure that this positive momentum is maintained and further amplified.”

Philip Morris International: Delivering a Smoke-Free Future

Philip Morris International (PMI) is a leading international tobacco company, actively delivering a smoke-free future and evolving its portfolio for the long term to include products outside of the tobacco and nicotine sector. The company’s current product portfolio primarily consists of cigarettes and smoke-free products. Since 2008, PMI has invested $12.5 billion to develop, scientifically substantiate, and commercialize innovative smoke-free products for adults who would otherwise continue to smoke, with the goal of completely ending the sale of cigarettes. This includes the building of world-class scientific assessment capabilities, notably in the areas of pre-clinical systems toxicology, clinical and behavioral research, as well as post-market studies. In 2022, PMI acquired Swedish Match—a leader in oral nicotine delivery—creating a global smoke-free champion led by the companies’ IQOS and ZYN brands. The U.S. Food and Drug Administration has authorized versions of PMI’s IQOS Platform 1 devices and consumables and Swedish Match’s General snus as Modified Risk Tobacco Products. As of December 31, 2023, PMI’s smoke-free products were available for sale in 84 markets, and PMI estimates that approximately 20.8 million adults around the world had already switched to IQOS and stopped smoking. Smoke-free products accounted for approximately 37 percent of PMI’s total full-year 2023 net revenues. With a strong foundation and significant expertise in life sciences, PMI announced in February 2021 its ambition to expand into wellness and healthcare areas and, through its Vectura Fertin Pharma business, aims to enhance life through the delivery of seamless health experiences. For more information, please visit www.pmi.com and www.pmiscience.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Philip Morris International
David Fraser
T. +41 (0)58 242 4500
E. David.Fraser@pmi.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Lineage Announces Closing of Initial Public Offering27.7.2024 00:19:00 EEST | Press release

Lineage, Inc. (the “Company”) (Nasdaq: LINE) today announced the closing of its underwritten initial public offering of 56,882,051 shares of its common stock at a public offering price of $78.00 per share. The net proceeds from the offering were approximately $4.2 billion, after deducting underwriting discounts and commissions and estimated expenses payable by the Company. The Company intends to use the net proceeds received from the offering to repay borrowings outstanding under its delayed draw term loan, repay borrowings outstanding under its revolving credit facility, fund one-time cash grants to certain of its employees in connection with this offering and estimated cash to pay tax withholding obligations associated with stock grants and redeem its Series A preferred stock. Following such uses, the Company expects to use the remaining net proceeds for general corporate purposes, which may include the repayment of additional borrowings outstanding under its revolving credit facilit

Introducing LEDGER FLEX — Easy, Secure Self-Custody, Free From Compromise26.7.2024 18:15:00 EEST | Press release

Ledger, the world leader in Digital Asset security for consumers and enterprises, today launched for sale Ledger Flex, its second new product launch in 2024. Released during Ledger’s tenth anniversary, Ledger Flex and the previously released Ledger Stax mark the inception of a new generation of Ledger hardware, featuring secure E Ink® touchscreen displays powered by Ledger’s Secure OS. Ledger Flex is available to purchase today on Ledger.com and through our retail partners around the world for $249, shipping immediately. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240726882083/en/ Ledger Flex™ (Photo: Business Wire) Ledger Flex marks the new standard for Ledger devices, featuring NFC and a secure E Ink® touchscreen, at an attractive price point. Ledger Flex is an homage to the iconic black and steel motif featured on Ledger devices for a decade, a reminder of Ledger’s heritage of uncompromising security. Its high-resoluti

LambdaTest Unveils Live Inspect for Enhanced App Automation Testing26.7.2024 18:00:00 EEST | Press release

LambdaTest, a leading cloud-based unified testing platform, introduces its latest offering, the Live Inspect feature for app automation testing. This tool empowers developers and testers to optimize their app automation processes with unparalleled live debugging capabilities directly from the LambdaTest automation dashboard. The Live Inspect feature allows users to interact with their automated test devices in real time, enhancing the efficiency and effectiveness of automated tests. With features such as real-time navigation, detailed UI element inspection, and screenshot capture, teams can now troubleshoot issues directly as they arise with their automation scripts, moving beyond mere video playback to active engagement with their applications. LambdaTest’s Live Inspect features include real-time interaction, which allows users to navigate their apps, inspect UI elements, capture screenshots, and generate unique custom xpaths while the automation script runs seamlessly. The enhanced U

Radico Khaitan comes onboard as the Official Partner for the first India House at The Paris 2024 Olympics26.7.2024 16:04:00 EEST | Press release

India House, the inaugural country house for the nation at the Paris 2024 Olympic Games, announces Radico Khaitan as the Official Partner. India House will serve as a home away from home for athletes as well as fans, commemorating 100 years since India first competed at the Olympic Games under the Indian Olympic Association in 1920. Radico Khaitan’s alliance with India House reaffirms the Company’s deep-rooted commitment to India’s growth and its vision to showcase the nation’s rich heritage and luxurious culture to the global audience. With a surge in sporting enthusiasm across India, it becomes imperative to empower our athletes and celebrate their success wherever they compete. Radico Khaitan is dedicated to boosting national morale at the Olympics and championing our athletes on the grand global stage. Through its contributions to India House, Radico Khaitan aims to spotlight India's opulence, culture, and legacy, fostering solidarity and pride among Indians worldwide in support of

Fujirebio Launches the Fully Automated Lumipulse ® G GFAP Assay for Research Use Only and Further Strengthens its Neuro Test Menu26.7.2024 14:00:00 EEST | Press release

H.U. Group Holdings Inc. and its wholly-owned subsidiary Fujirebio today announced the availability of the Lumipulse G GFAP assay for the fully automated, random-access LUMIPULSE® G immunoassay systems. The Research Use Only (RUO) assay is now available in the United States, and it will be available in Japan, Europe and other regions* as of September this year. The Chemiluminescent Enzyme Immunoassay (CLEIA) test allows for the quantitative measurement of glial fibrillary acidic protein (GFAP) in human plasma and serum in just 35 minutes. “In 2023 we already introduced two new important neuro assays for RUO-based detection of Neurofilament Light (NfL) and pTau 217,” said Goki Ishikawa, President and CEO of Fujirebio Holdings, Inc. “We continue our engagement in biomarker-based testing for neurological diseases with the Lumipulse G GFAP, affirming our commitment to play an essential partnering role in both research and clinical routine.” The Lumipulse G GFAP assay will allow the scienti

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
HiddenA line styled icon from Orion Icon Library.Eye